Sep 29, 2022 / 02:30PM GMT
Ahu Demir - Ladenburg Thalmann & Co. Inc. - Analyst
Thanks for coming, joining us for Salarius fireside chat. We will initiate it with a quick presentation from David Arthur, the CEO of Salarius. Thank you so much, David. Thanks for joining us today.
David Arthur - Salarius Pharmaceuticals, Inc. - CEO
Well, thank you so much for inviting us.
Ahu Demir - Ladenburg Thalmann & Co. Inc. - Analyst
Please take it away so we can start with the presentation first.
David Arthur - Salarius Pharmaceuticals, Inc. - CEO
Happy to. Good morning, everybody. I'm David Arthur, CEO of Salarius Pharmaceuticals. And joining me today is Mark Rosenblum, Chief Financial Officer; Dr. Daniela Santiesteban, Director of our Protein Degradation Development program; and Dr. Aundrietta Duncan, Director of Nonclinical Development.
So we have a brain trust here to really help talk about Salarius, which is great because it's an exciting story. And I'm going to steal a line from Mark. A lot
Salarius Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot